NCCN issues revised prostate cancer management guidelines for 2016

The National Comprehensive Cancer Consortium (NCCN) has just released its updated 2016 guidelines on the management of prostate cancer for physicians. … READ MORE …

Assessing the “value” of treatment with specific drugs (here in the USA)

Last Friday, the National Comprehensive Cancer Cancer Network (NCCN) introduced a new way for doctors and patients to be able to consider the clinical “value” of treatment with specific drugs in specific forms of cancer. How useful this method is will take a while to work out. … READ MORE …

NCCN issues cancer “survivorship” guidelines for clinicians

According to a report on the Medscape Oncology web site this morning, the National Comprehensive Cancer Network (NCCN) has just released, for the first time, guidelines for clinicians that address factors affecting “survivorship” after a diagnosis of and treatment for cancer. … READ MORE …

The new NCCN patient guidelines — a great improvement over last time

We have now had the chance to look carefully through the new, patient-specific guidelines on prostate cancer issued by the National Comprehensive Cancer Network (NCCN) just before the Holidays. They are not perfect, but they are certainly a vast improvement over the NCCN’s first attempt. … READ MORE …

NCCN issues completely revised edition of prostate cancer patient guidelines

The “New” Prostate Cancer InfoLink is pleased to see that — here in the USA — the National Comprehensive Cancer Network (NCCN) has just issued a fully revised, new edition of the NCCN Guidelines for Patients™ for Prostate Cancer (Version 1.2011). … READ MORE …

NCCN issues patient guidelines on prostate cancer diagnosis and management

At some point in the past 3 weeks or so, the National Comprehensive Cancer Network (NCCN) Foundation has quietly issued its new NCCN Guidelines for Patients™ on prostate cancer diagnosis and management. … READ MORE …

NCCN gives strong endorsement for sipuleucel-T

The National Comprehensive Cancer Network has updated its prostate cancer management guidelines to give a category 1 recommendation for clinical use of sipuleucel-T (Provenge) in the treatment of selected patients. … READ MORE …